Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by autoantibody production and organ damage. Lupus nephritis (LN) is one of the most severe manifestations of SLE. Multiple studies reported associations between renal diseases and variants in the non-muscle myosin heavy chain 9 (MYH9) and the neighboring apolipoprotein L 1 (APOL1) genes. We evaluated 167 variants spanning MYH9 for association with LN in a multiethnic sample. The two previously identified risk variants in APOL1 were also tested for association with LN in European-Americans (EAs) (N=579) and African-Americans (AAs) (N=407). Multiple peaks of association exceeding a Bonferroni corrected P-value of P<2.03 × 10−3 were observed between LN and MYH9 in EAs (N=4620), with the most pronounced association at rs2157257 (P=4.7 × 10−4, odds ratio (OR)=1.205). A modest effect with MYH9 was also detected in Gullah (rs8136069, P=0.0019, OR=2.304). No association between LN and MYH9 was found in AAs, Asians, Amerindians or Hispanics. This study provides the first investigation of MYH9 in LN in non-Africans and of APOL1 in LN in any population, and presents novel insight into the potential role of MYH9 in LN in EAs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hart HH, Grigor RR, Caughey DE . Ethnic difference in the prevalence of systemic lupus erythematosus. Ann Rheum Dis 1983; 42: 529–532.
Bae SC, Fraser P, Liang MH . The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the ‘prevalence gradient hypothesis’. Arthritis Rheum 1998; 41: 2091–2099.
Serdula MK, Rhoads GG . Frequency of systemic lupus erythematosus in different ethnic groups in Hawaii. Arthritis Rheum 1979; 22: 328–333.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.
Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
Wallace DJ, Hahn B, Dubois EL . Dubois’ Lupus Erythematosus 6th edn, Lippincott Williams & Wilkins: Philadelphia, 2002, xiii, 1348 pp.
Cameron JS . Lupus nephritis. J Am Soc Nephrol 1999; 10: 413–424.
Cameron JS . Lupus nephritis: an historical perspective 1968–1998. J Nephrol 1999; 12 (Suppl 2): S29–S41.
Bastian HM, Roseman JM, McGwin Jr G, Alarcon GS, Friedman AW, Fessler BJ et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 152–160.
Mok CC, Lau CS . Lupus in Hong Kong Chinese. Lupus 2003; 12: 717–722.
Wong SN, Tse KC, Lee TL, Lee KW, Chim S, Lee KP et al. Lupus nephritis in Chinese children—a territory-wide cohort study in Hong Kong. Pediatr Nephrol 2006; 21: 1104–1112.
Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, Divers J et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009; 75: 736–745.
Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185–1192.
Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175–1184.
Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, Bercovici S et al. African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Hum Mol Genet 2010; 19: 1816–1827.
Kunishima S, Saito H . Advances in the understanding of MYH9 disorders. Curr Opin Hematol 2010; 17: 405–410.
Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841–845.
Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, Bernhardy AJ et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010; 78: 698–704.
Zenker M, Mertens PR . Arrest of the true culprit and acquittal of the innocent? Genetic revelations charge APOL1 variants with kidney disease susceptibility. Int Urol Nephrol 2010; 42: 1131–1134.
Freedman BI, Edberg JC, Comeau ME, Murea M, Bowden DW, Divers J et al. The non-muscle myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. Am J Nephrol 2010; 32: 66–72.
Saban Elitok UG, Markus B, Mato N, Wolfgang S, Ralph K, Friedrich CL . MYH9 mutation and lupus erythematosus. NDT Plus 2010; 3: 128–131.
Reville K, Crean JK, Vivers S, Dransfield I, Godson C . Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J Immunol 2006; 176: 1878–1888.
Marigo V, Nigro A, Pecci A, Montanaro D, Di Stazio M, Balduini CL et al. Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics 2004; 83: 1125–1133.
Mok CC . Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010; 2010: 638413.
Murea M, Freedman BI . Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens 2010; 19: 235–241.
Nelson GW, Freedman BI, Bowden DW, Langefeld CD, An P, Hicks PJ et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet 2010; 19: 1805–1815.
Kamen DL, Barron M, Parker TM, Shaftman SR, Bruner GR, Aberle T et al. Autoantibody prevalence and lupus characteristics in a unique African American population. Arthritis Rheum 2008; 58: 1237–1247.
Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A et al. A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet 2004; 74: 1001–1013.
Halder I, Shriver M, Thomas M, Fernandez JR, Frudakis T . A panel of ancestry informative markers for estimating individual biogeographical ancestry and admixture from four continents: utility and applications. Hum Mutat 2008; 29: 648–658.
McKeigue PM, Carpenter JR, Parra EJ, Shriver MD . Estimation of admixture and detection of linkage in admixed populations by a Bayesian approach: application to African-American populations. Ann Hum Genet 2000; 64 (Part 2): 171–186.
Hoggart CJ, Parra EJ, Shriver MD, Bonilla C, Kittles RA, Clayton DG et al. Control of confounding of genetic associations in stratified populations. Am J Hum Genet 2003; 72: 1492–1504.
Hoggart CJ, Shriver MD, Kittles RA, Clayton DG, McKeigue PM . Design and analysis of admixture mapping studies. Am J Hum Genet 2004; 74: 965–978.
Howie BN, Donnelly P, Marchini J . A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.
Via M, Gignoux C, Burchard EG . The 1000 Genomes Project: new opportunities for research and social challenges. Genome Med 2010; 2: 3.
Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851–861.
Marchini J, Howie B . Genotype imputation for genome-wide association studies. Nat Rev Genet 2010; 11: 499–511.
Marchini J, Howie B, Myers S, McVean G, Donnelly P . A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39: 906–913.
Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661–678.
Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21: 1422–1426.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
Barrett JC . Haploview: visualization and analysis of SNP genotype data. CSH Protoc 2009; 2009: pdb ip71.
Acknowledgements
We thank all study participants, SLE and controls in this study as well as all the staff who assisted in their recruitment. We gratefully acknowledge the following individuals for their generous contribution in genotyping samples: Dr Peter K Gregersen, Drs Sandra D’Alfonso (Italy), Rafaella Scorza (Italy), Peter Junker and Helle Laustrup (Denmark), Marc Bijl (Holland), Emoke Endreffy (Hungary), Carlos Vasconcelos and Berta Martins da Silva (Portugal), Ana Suarez and Carmen Gutierrez (Spain), Iñigo Rúa-Figueroa (Spain) and Dr Cintia Garcilazo (Argentina). For the AADEA collaboration: Norberto Ortego-Centeno (Spain), Juan Jimenez-Alonso (Spain), Enrique de Ramon (Spain) and Julio Sanchez-Roman (Spain). For the GENLES collaboration: Dr Mario Cardiel (Mexico), Dr Ignacio García de la Torre (Mexico), Marco Maradiaga (Mexico), José F Moctezuma (Mexico), Dr Eduardo Acevedo (Peru), Cecilia Castel and Mabel Busajm (Argentina), Jorge Musuruana (Argentina). Other participants from the Argentine Collaborative Group are: Hugo R Scherbarth MD, Pilar C Marino MD, Estela L Motta MD; Susana Gamron MD, Cristina Drenkard MD, Emilia Menso MD; Alberto Allievi MD, Guillermo A Tate MD; Jose L Presas MD; Simon A Palatnik MD, Marcelo Abdala MD, Mariela Bearzotti PhD; Alejandro Alvarellos MD, Francisco Caeiro MD, Ana Bertoli MD; Sergio Paira MD, Susana Roverano MD; Cesar E Graf MD, Estela Bertero PhD; Carolina Guillerón MD, Sebastian Grimaudo PhD, Jorge Manni MD; Luis J Catoggio MD, Enrique R Soriano MD, Carlos D Santos MD; Cristina Prigione MD, Fernando A Ramos MD, Sandra M Navarro MD; Guillermo A Berbotto MD, Marisa Jorfen MD, Elisa J Romero PhD; Mercedes A Garcia MD, Juan C Marcos MD, Ana I Marcos MD; Carlos E Perandones MD, Alicia Eimon MD; Cristina G Battagliotti MD. We also would like to knowledge Mary C Comeau MA; Miranda C Marion MA; Paula S Ramos PhD; Summer Frank MPH and Mai Li Zhu MS for their assistance in genotyping, quality control analyses and clinical data management, and everyone at the Lupus Family Registry and Repository (LFRR) for data collection and maintenance. The work has been funded principally by the US National Institutes of Health grants R01 AI063274 and R01 AR056360 (PMG); R01 AR043274 (KLM); N01 AR62277, R37 24717, R01 AR042460, P01 AI083194, P20 RR020143, R01 DE018209 (JBH); P01 AR49084 (RPK and EEB); R01 AR33062 (RPK); P30 AR055385 (EEB); K08 AI083790, LRP AI071651, UL1 RR024999 (TBN); R01CA141700, RC1 AR058621 (MEAR); R01AR051545-01A2, ULI RR025014-02 (AMS); P30 AR053483, N01 AI50026 (JAJ and JMG); P20 RR015577 (JAJ); R21 AI070304 (SAB); P30 RR031152, U19 AI082714, P30 AR053483, RC1 AR05884 (JAJ and JMG); R01 AR43814 (BPT); P60 AR053308, M01 RR-00079 (LAC); R01 AR043727, UL1 RR025005 (MAP); K24 AR002138, P60-2 AR30692, P01 AR49084, UL1RR025741 (RRG); UL1 RR029882, P60 AR049459 (GSG and DLK). A portion of this study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A080588; SCB). Additional support was granted from the Alliance for Lupus Research (KLM); Merit Award from the US Department of Veterans Affairs (JBH and GSG); the Swedish Research Council for Medicine, Gustaf Vth-80th Jubilee Fund and Swedish Association Against Rheumatism, Instituto de Salud Carlos III, Oklahoma Center for Advancement of Science and Technology (OCAST) HR09-106 (MEAR); the European Science Foundation funds the BIOLUPUS network (MEAR coordinator); Federico Wilhelm Agricola Foundation Research grant (BPE); The Barrett Scholarship Fund OMRF (CJL); Lupus Research Institute (TBN, BPT); The Alliance for Lupus Research (TBN, LAC, MEAR and COJ); the Arthritis National Research Foundation Eng Tan Scholar Award (TBN); Arthritis Foundation (PMG and AMS); the Lupus Foundation of Minnesota (PMG and KLM); the Wellcome Trust (TJV); Arthritis Research UK (TJV); Kirkland Scholar Award (LAC, JAJ) and Wake Forest University Health Sciences Center for Public Health Genomics (CDL). The work reported on in this publication has been in part financially supported by the ESF, in the framework of the Research Networking Programme European Science Foundation-The Identification of Novel Genes and Biomarkers for Systemic Lupus Erythematosus (BIOLUPUS) 07-RNP-083.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Genes and Immunity website
Supplementary information
Rights and permissions
About this article
Cite this article
Lin, C., Adrianto, I., Lessard, C. et al. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 13, 232–238 (2012). https://doi.org/10.1038/gene.2011.82
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gene.2011.82
Keywords
This article is cited by
-
A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus
Clinical Reviews in Allergy & Immunology (2022)
-
Transcriptome Studies in Lupus Nephritis
Archivum Immunologiae et Therapiae Experimentalis (2022)
-
Effect of donor non-muscle myosin heavy chain (MYH9) gene polymorphisms on clinically relevant kidney allograft dysfunction
BMC Nephrology (2020)
-
Lupus nephritis
Nature Reviews Disease Primers (2020)
-
Distinct proteome pathology of circulating microparticles in systemic lupus erythematosus
Clinical Proteomics (2017)